Semax vs Selank: How the Research Compares

What are Semax and Selank?

Semax and Selank came out of the same Russian research network, centered on the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. Both are heptapeptides, both end in Pro-Gly-Pro, and both were designed as hybrids: a short, biologically active fragment of a natural peptide joined to a glyproline tail^1,2,3.

Glyprolines are proline- and glycine-containing peptides that Moscow physiologists reported to be far more stable in the body than typical regulatory peptides; adding Pro-Gly-Pro was meant to protect the active fragment from rapid breakdown³. Both peptides are still metabolized. Tritium-labeling studies identified His-Phe-Pro-Gly-Pro and Pro-Gly-Pro as the main products of Semax breakdown in the presence of nerve cells, and Thr-Lys-Pro-Arg-Pro, Thr-Lys-Pro, Arg-Pro and Gly-Pro as the main products of Selank breakdown in blood plasma⁴.

The difference lies in the front half. Semax begins with Met-Glu-His-Phe, the 4-7 segment of adrenocorticotropic hormone (ACTH), and is described as an analog of ACTH(4-10)¹. Selank begins with Thr-Lys-Pro-Arg, the sequence of tuftsin, and is described as an analog of that immunomodulatory peptide^5,6.

Semax vs Selank at a glance

The table summarizes how the two compare on structure, the targets researchers have examined, and the state of the evidence. Details and citations follow in the sections below.

Semax research: BDNF and ischemia models

The core Semax finding is rapid induction of brain-derived neurotrophic factor (BDNF), a growth factor involved in synaptic plasticity. In the rat hippocampus, Semax raised BDNF protein, phosphorylation of the BDNF receptor TrkB, and BDNF and TrkB mRNA, and treated rats made more conditioned avoidance responses in a learning task¹.

In rat models of stroke-like injury, Semax increased transcription of neurotrophin genes and their receptors in ischemic cortex after permanent middle cerebral artery occlusion, whereas the Pro-Gly-Pro fragment alone acted mainly non-specifically⁷. After transient occlusion with reperfusion, RNA sequencing found that Semax suppressed inflammation-related genes and activated neurotransmission-related genes, roughly reversing the pattern caused by the injury itself⁸. These studies measure gene expression at set time points in rats; they do not establish long-term functional outcomes.

Selank research: GABA, enkephalins and stress models

Selank's mechanism has been approached from several angles. Radioligand studies on brain cell membranes suggest it acts as a positive allosteric modulator of GABA receptors and that it alters the binding effects of diazepam and olanzapine². Earlier work showed that Selank inhibited enkephalin-degrading enzymes in human plasma more potently than bacitracin or puromycin; the researchers proposed this as a possible basis for the anxiolytic-like activity reported in animal studies⁹.

Selank has also been studied in rodent stress and exposure models. In rats given ethanol long term, it prevented ethanol-related changes in hippocampal and prefrontal BDNF content and the memory deficits seen in an object recognition test during withdrawal⁶. So BDNF appears in both literatures, but in different models: healthy rat brain for Semax, an alcohol-exposure model for Selank.

Where Semax and Selank overlap

The two peptides have been tested side by side in a few studies. In the same in vitro experiment, both inhibited enkephalin-degrading enzymes in human serum, with Semax slightly more potent; pentapeptide fragments of each retained activity, while tri-, tetra- and hexapeptide fragments did not¹⁰.

In a rat model of Parkinson-like dopamine-neuron damage induced with 6-OHDA, neither peptide changed motor activity or passive defensive behavior, but Selank reduced anxiety-like behavior in an elevated maze, matching earlier findings in healthy rodents⁵. In people, a resting-state fMRI study in 52 healthy participants scanned the brain before and 5 and 20 minutes after Semax, Selank or placebo, and reported both shared and peptide-specific changes in functional connectivity between the right amygdala and the right temporal cortex¹¹.

Human studies and regulatory status

Human research on both peptides is small and almost entirely Russian. For Semax, the clearest data are short imaging studies in healthy volunteers such as the head-to-head study above¹¹. For Selank, two clinical studies of 62 and 60 patients with anxiety-related diagnoses compared it with the benzodiazepines medazepam and phenazepam, using standard rating scales and, in one, serum enkephalinase activity; neither used a placebo group^12,13.

Russian authors describe Semax as a medicine used in Russia for patients with cerebral circulation disorders⁸. US pharmacists have described Selank as a poorly studied Russian drug with GABAergic mechanisms that was being sold to US consumers as a dietary supplement¹⁴. Belgian control-laboratory scientists who identified both peptides in seized preparations described them as research peptides sold online that, to their knowledge, had not completed clinical trials¹⁵. Neither peptide is approved by the FDA or the European Medicines Agency.

Limitations of the evidence

The two literatures share the same weaknesses. Most studies come from a small set of Moscow institutes, and the Semax and Selank papers often share authors. Endpoints are frequently mRNA levels measured hours after a single exposure in rodents, which show that a peptide changes gene expression but not whether those changes matter for function. Independent replication outside Russia is rare, the human studies are small, and several clinical papers are available only as Russian-language articles with short English abstracts.

• No specific receptor has been characterized for either peptide.
• Behavioral results come mostly from rodent stress and learning tasks.
• Clinical comparisons used active drugs rather than placebo.
• Regulators outside Russia have not evaluated either compound.

Choosing between Semax and Selank for research

The practical difference is the question being asked. Semax fits work on neurotrophin signaling, BDNF and ischemia models; Selank fits work on GABAergic modulation, enkephalin metabolism and stress behavior. Both are available individually as Semax and Selank, and together with Pinealon in the Semax / Selank / Pinealon Set.

Every Peptides Only lot is independently tested and ships from the USA with a lot-matched certificate of analysis showing HPLC purity and mass-spec identity, published in our certificate library. Our guide on how to read a peptide COA explains what those results mean.